Among the signal transduction pathways involved in adaptive cancer response to therapy are tyrosine kinase receptors (RTKs) regulated by NRP1, such as EGFR and IGF1-R, and intracellular effectors, such as PI3K/AKT, MAPK/ERK or NF-κB [28,29]. The gene discussed is EGFR; the disease is cancer.